EADV26: Key late-stage readouts from the conference
In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm …
Post
-
-
Surrozen secures FDA clearance for SZN-8141 clinical trial
The US Food and Drug Administration (FDA) has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin clinical …
-
Genmab reports Phase I/II data for Rina-S in ovarian cancer
Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients …
-
Brainomix’s e-Lung shows progression and treatment response in Phase III trial
Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its AI-powered …
-
EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, retrospective research was presented that showed initial …
-
Brainomix’s e-Lung shows progression and treatment response in Phase III trial
Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its AI-powered …
-
EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, retrospective research was presented that showed initial …
-
EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
Regeneron Pharmaceuticals’ Phase II trial of its muscle-preservation drug for patients using glucagon-like peptide-1 receptor agonists (GLP-1RAs) has met its …
-
EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
EASD 2026: Semaglutide shows promise in treating obesity-related heart failure
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, research was presented that showed encouraging results …
-
Zealand dips on Boehringer-paired obesity drug’s Phase III result
Zealand Pharma’s share price fell by 12% after its partnered obesity hopeful, survodutide, failed to impress in a Phase III …
-
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
Rafael Holdings subsidiary, Cyclo Therapeutics, is forging on with regulatory submissions for its rare metabolic disease therapy despite the drug …
-
Podcast: Data beyond a study’s main objective provide strategic insights
By undertaking additional analysis of clinical data, study results can yield potentially valuable insights beyond a study's primary objective. Post-hoc analyses …
